{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:24:03Z","timestamp":1787009043221,"version":"build-2736575974"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Aminoglycosides, once less favoured compared with \u03b2-lactams (BLs) for treating urinary tract infections (UTIs), have gained attention due to the rising prevalence of ESBL-producing Enterobacterales. However, comparative data on the efficacy and safety of aminoglycosides versus BLs are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively compared patients with Gram-negative bacteraemic UTIs, who received monotherapy with aminoglycosides or BLs for at least 3\u2005days. The primary outcome was clinical improvement at 72\u2005h. Secondary outcomes included clinical improvement by discharge, time to improvement, mortality, length of stay, relapse rate and kidney injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of 134 patients, 96 received BLs and 38 received aminoglycosides. BL recipients had more comorbidities, renal failure and higher clinical severity of bacteraemia. Clinical improvement for BLs versus aminoglycosides was similar at 72\u2005h (55% versus 65.8%, P\u200a=\u200a0.335) and by discharge (87.5% versus 94.7%, P\u200a=\u200a0.663). A multivariate analysis accounting for baseline differences showed similar efficacy at both timepoints, with ORs for improvement for BLs versus aminoglycosides of 1.52 (95% CI 0.54\u20134.31). Hospital stay was 1.7\u2005days shorter with aminoglycosides. Other secondary outcomes were not different between groups. Kidney injury was more common with aminoglycosides, but this difference was not significant and was not found when the analysis was limited to patients with a creatinine level of &amp;lt;1.5\u2005mg\/dL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this cohort of bacteraemic patients with UTI, aminoglycosides were associated with similar outcomes as BLs, with no significant risk of toxicity. Given their broad Gram-negative coverage and favourable pharmacokinetics, aminoglycosides could be reconsidered as a first-line treatment option for UTIs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlaf126","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T10:16:57Z","timestamp":1752833817000},"source":"Crossref","is-referenced-by-count":2,"title":["Aminoglycoside versus \u03b2-lactam treatment for urosepsis\u2014a retrospective cohort study"],"prefix":"10.1093","volume":"7","author":[{"given":"Amos","family":"Cahan","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Samson Assuta Ashdod University Hospital , Harefua St. 7, Ashdod 7747629 ,","place":["Israel"]},{"name":"Faculty of Health Sciences, Ben Gurion University of the Negev , Beer Sheba ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Peleg","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Ben Gurion University of the Negev , Beer Sheba ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadav","family":"Sorek","sequence":"additional","affiliation":[{"name":"Microbiology Laboratory, Samson Assuta Ashdod University Hospital , Ashdod ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7154-2032","authenticated-orcid":false,"given":"Tal","family":"Brosh-Nissimov","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Samson Assuta Ashdod University Hospital , Harefua St. 7, Ashdod 7747629 ,","place":["Israel"]},{"name":"Faculty of Health Sciences, Ben Gurion University of the Negev , Beer Sheba ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"2025071806165284500_dlaf126-B1","author":"Bonkat"},{"key":"2025071806165284500_dlaf126-B2","author":"NICE"},{"key":"2025071806165284500_dlaf126-B3","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2025071806165284500_dlaf126-B4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2025071806165284500_dlaf126-B5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/SHK.0b013e318182f98f","article-title":"Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the acute physiology and chronic health evaluation II scoring systems","volume":"31","author":"Rhee","year":"2009","journal-title":"Shock"},{"key":"2025071806165284500_dlaf126-B6","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2021"},{"key":"2025071806165284500_dlaf126-B7","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J Open Source Softw"},{"key":"2025071806165284500_dlaf126-B8","author":"Wickham"},{"key":"2025071806165284500_dlaf126-B9","author":"Yoshida"},{"key":"2025071806165284500_dlaf126-B10","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1128\/AAC.41.5.1127","article-title":"Monotherapy versus \u03b2-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study","volume":"41","author":"Leibovici","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2025071806165284500_dlaf126-B11","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3390\/ph6111335","article-title":"A review of ten years of the study for monitoring antimicrobial resistance trends (SMART) from 2002 to 2011","volume":"6","author":"Morrissey","year":"2013","journal-title":"Pharmaceuticals"},{"key":"2025071806165284500_dlaf126-B12","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1128\/CMR.00023-13","article-title":"Trends in human fecal carriage of extended-spectrum \u03b2-lactamases in the community: toward the globalization of CTX-M","volume":"26","author":"Woerther","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"2025071806165284500_dlaf126-B13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1017\/ice.2015.239","article-title":"Increasing incidence of extended-spectrum \u03b2-lactamase-producing Escherichia coli in community hospitals throughout the Southeastern United States","volume":"37","author":"Thaden","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2025071806165284500_dlaf126-B14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1186\/s12879-015-1282-4","article-title":"Ciprofloxacin resistance in community- and hospital-acquired Escherichia coli urinary tract infections: a systematic review and meta-analysis of observational studies","volume":"15","author":"Fasugba","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2025071806165284500_dlaf126-B15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/jac\/dky424","article-title":"Risk analysis of antimicrobial resistance in outpatient urinary tract infections of young healthy adults","volume":"74","author":"Brosh-Nissimov","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025071806165284500_dlaf126-B16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3949\/ccjm.69.4.289","article-title":"How to prevent, recognize, and treat drug-induced nephrotoxicity","volume":"69","author":"Guo","year":"2002","journal-title":"Cleve Clin J Med"},{"key":"2025071806165284500_dlaf126-B17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1093\/jac\/37.4.645","article-title":"A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses","volume":"37","author":"Munckhof","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"2025071806165284500_dlaf126-B18","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/ajhp\/53.10.1141","article-title":"Effectiveness and safety of once-daily aminoglycosides: a meta-analysis","volume":"53","author":"Ferriols-Lisart","year":"1996","journal-title":"Am J Health Syst Pharm"},{"key":"2025071806165284500_dlaf126-B19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/bcp.13439","article-title":"Adverse effects of a single dose of gentamicin in adults: a systematic review","volume":"84","author":"Hayward","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2025071806165284500_dlaf126-B20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.cmi.2020.06.030","article-title":"Renal safety of a single dose of gentamicin in patients with sepsis in the emergency department","volume":"27","author":"Cobussen","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2025071806165284500_dlaf126-B21","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/jac\/dkm193","article-title":"Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials","volume":"60","author":"Vidal","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2025071806165284500_dlaf126-B22","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/01.JU.0000576820.06238.8b","article-title":"Re: Once-daily plazomicin for complicated urinary tract infections","volume":"202","author":"Wagenlehner","year":"2019","journal-title":"J Urol"},{"key":"2025071806165284500_dlaf126-B23","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1093\/jac\/dku215","article-title":"The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum \u03b2-lactamase-producing Escherichia coli","volume":"69","author":"Park","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2025071806165284500_dlaf126-B24","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1093\/jac\/dkw499","article-title":"Gut-sparing treatment of urinary tract infection in patients at high risk of Clostridium difficile infection","volume":"72","author":"Staley","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025071806165284500_dlaf126-B25","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1093\/jac\/dkaa148","article-title":"Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis","volume":"75","author":"Elbaz","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025071806165284500_dlaf126-B26","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/jac\/dkz457","article-title":"Aminoglycoside versus carbapenem or piperacillin\/tazobactam treatment for bloodstream infections of urinary source caused by Gram-negative ESBL-producing Enterobacteriaceae","volume":"75","author":"Zohar","year":"2020","journal-title":"J Antimicrob Chemother"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/4\/dlaf126\/63793464\/dlaf126.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/4\/dlaf126\/63793464\/dlaf126.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T10:16:59Z","timestamp":1752833819000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlaf126\/8205982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlaf126","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,7,2]]},"article-number":"dlaf126"}}